BridgeBio PharmaBBIO
- Legal name
- BridgeBio Pharma, Inc.
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Exchange
- Nasdaq
Stock Price $BBIO
Latest filings
You are here#58 of 59 in Healthcare by market cap
Area = market cap · hover a tile to read it
BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.
- 8-K · Jul 3, 2019
- 10-Q · Aug 14, 2019
- 8-K · Sep 12, 2019
- 8-K · Oct 11, 2019
- 10-Q · Nov 8, 2019
- 8-K · Nov 19, 2019
- 8-K · Dec 17, 2019
- 8-K · Dec 26, 2019
- 8-K · Jan 7, 2020
- 8-K · Feb 19, 2020
- 8-K · Mar 2, 2020
- 10-K · Mar 3, 2020
- 8-K · Mar 4, 2020
- 8-K · Mar 6, 2020
- 8-K · Mar 10, 2020
- 8-K · Mar 24, 2020
- 8-K · Apr 29, 2020
- 8-K · May 13, 2020
- 10-Q · May 14, 2020
- 8-K · Jun 8, 2020
- 8-K · Jun 24, 2020
- 8-K · Aug 11, 2020
- 10-Q · Aug 11, 2020
- 8-K · Sep 29, 2020
- 8-K · Oct 5, 2020
- 8-K · Oct 6, 2020
- 8-K · Oct 23, 2020
- 10-Q · Nov 5, 2020
- 8-K · Nov 5, 2020
- 8-K · Nov 6, 2020
- 8-K · Jan 4, 2021
- 8-K · Jan 12, 2021
- 8-K · Jan 20, 2021
- 8-K · Jan 26, 2021
- 8-K · Jan 26, 2021
- 8-K · Jan 29, 2021
- 8-K · Feb 17, 2021
- 10-K · Feb 25, 2021
- 8-K · Feb 26, 2021
- 8-K · Mar 31, 2021
- 8-K · Apr 15, 2021
- 10-Q · May 6, 2021
- 8-K · May 11, 2021
- 8-K · May 14, 2021
- 8-K · Jun 1, 2021
- 8-K · Jun 22, 2021
- 10-Q · Aug 5, 2021
- 8-K · Aug 13, 2021
- 8-K · Aug 23, 2021
- 8-K · Oct 26, 2021
- 8-K · Nov 4, 2021
- 10-Q · Nov 4, 2021
- 8-K · Nov 18, 2021
- 8-K · Dec 16, 2021
- 8-K · Dec 27, 2021
- 8-K · Feb 24, 2022
- 10-K · Feb 25, 2022
- 10-Q · May 5, 2022
- 8-K · May 10, 2022
- 8-K · May 13, 2022
- 8-K · May 18, 2022
- 8-K · Jun 24, 2022
- 8-K · Jul 26, 2022
- 10-Q · Aug 4, 2022
- 8-K · Aug 4, 2022
- 8-K · Sep 23, 2022
- 10-Q · Nov 3, 2022
- 8-K · Nov 3, 2022
- 8-K · Dec 6, 2022
- 8-K · Feb 23, 2023
- 10-K · Feb 23, 2023
- 8-K · Mar 6, 2023
- 8-K · Mar 9, 2023
- 8-K · May 4, 2023
- 10-Q · May 4, 2023
- 8-K · May 4, 2023
- 8-K · Jun 22, 2023
- 8-K · Jul 17, 2023
- 8-K · Aug 3, 2023
- 10-Q · Aug 3, 2023
- 8-K · Sep 25, 2023
- 10-Q · Nov 2, 2023
- 8-K · Nov 2, 2023
- 8-K · Jan 8, 2024
- 8-K · Jan 18, 2024
- 10-K · Feb 22, 2024
- 8-K · Feb 22, 2024
- 8-K · Mar 4, 2024
- 8-K · Mar 6, 2024
- 8-K · May 2, 2024
- 10-Q · May 2, 2024
- 8-K · Jun 6, 2024
- 8-K · Jun 24, 2024
- 8-K · Jul 23, 2024
- 10-Q · Aug 1, 2024
- 8-K · Aug 1, 2024
- 8-K · Aug 21, 2024
- 8-K · Sep 11, 2024
- 10-Q · Nov 12, 2024
- 8-K · Nov 12, 2024
- 8-K · Nov 25, 2024
- 8-K · Jan 13, 2025
- 10-K · Feb 20, 2025
- 8-K · Feb 20, 2025
- 8-K · Feb 28, 2025
- 8-K · Mar 17, 2025
- 8-K · Apr 29, 2025
- 10-Q · Apr 29, 2025
- 8-K · Jun 23, 2025
- 8-K · Jul 2, 2025
- 10-Q · Aug 5, 2025
- 8-K · Aug 5, 2025
- 8-K · Oct 27, 2025
- 8-K · Oct 29, 2025
- 10-Q · Oct 29, 2025
- 8-K · Oct 29, 2025
- 8-K · Jan 12, 2026
- 8-K · Jan 21, 2026
- 8-K · Feb 12, 2026
- 8-K · Feb 24, 2026
- 10-K · Feb 24, 2026
- 8-K · Mar 30, 2026
- 10-Q · May 7, 2026
- 8-K · May 7, 2026
- 8-K · May 8, 2026
- 8-K · May 13, 2026
- 8-K · May 27, 2026
- 8-K · Jun 26, 2026
- 8-K · Jul 2, 2026
- 8-K · Jul 22, 2026
- 8-K · Aug 10, 2026
- 10-Q · Aug 10, 2026
- 8-K · Aug 17, 2026
- 8-K · Aug 31, 2026
- 8-K · Oct 13, 2026
- 8-K · Oct 29, 2026
- 10-Q · Oct 29, 2026
01—Key figures
Revenue Trend
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025
- $502.1M
2 older moves run past ±150% (largest +2285.3%); point at, tap or drag across the bars to read one.
Latest bar from 10-KFY2025Click a bar to open its SEC filingTap a bar to open its SEC filing
View full history →All BBIO Financial Metrics62 metrics
Income Statement17
Balance Sheet27
- Cash & ST Investments
- Total Assets
- Current Assets
- Cash
- Short-Term Investments
- Receivables
- Inventory
- Prepaid & Other
- PP&E
- Intangibles
- Other Non-current
- Total Liabilities
- Current Liabilities
- Accounts Payable
- Accrued Liabilities
- Short-Term Debt
- Deferred Revenue
- Long-Term Debt
- Other Non-current Liab.
- Equity
- Retained Earnings
- Accumulated OCI
- APIC
- Treasury Stock
- NCI
- Total L&E
- Shares Outstanding
Cash Flow14
02—Overview
BridgeBio Pharma Financial Overview 2021–2025
Updated Nov 5, 2026Attruby generated $362.4 milliona of net product revenue in FY2025, up from just $2.9 million in FY2024. That is roughly a 125-fold jump in one year, and it matters because BridgeBio spent years as a cash-burning pipeline story. The core thesis: the ATTR-CM launch proves the company can sell, but losses and leverage still define the balance sheet.
Revenue rose from $69.7 millionb in FY2021, nearly all of it license income, to $502.1 million in FY2025. Spending rose faster. Net loss widened from $586.5 million to $732.9 million over the same span, and the accumulated deficit reached $3.8 billion. SG&A climbed to $531.2 million in FY2025 from $288.9 million a year earlier, mostly launch costs. Year-end cash and marketable securities were $587.5 million, set against $1.9 billion of convertible notes and $866.3 million of deferred royalty obligations. Stockholders' deficit stood at $2.08 billion.
The market looked past the losses. At the close of FY2025 (December 30, 2025), shares traded at $76.49c, for a market cap of $14.9 billion, about 30x that year's revenue. With EPS at -$3.78, a P/E is not meaningful, so the valuation rests entirely on growth. Momentum continued into Q3 2026: revenue hit $353.2 million, net loss narrowed to $60.5 million, and cash rose to $1.54 billion after a $933.9 million preferred stock sale.
Recent Developments (Q2 and Q3 2026)
Attruby sales climbed through Q2 2026 and Q3 2026, with U.S. net product revenue up roughly $31 million sequentially in Q3 2026 to $253.2 milliond. Loss from operations narrowed to $11.6 million from $145.2 million a year earlier, helped by a $75.0 million Bayer sales milestone. Three NDAs now hold Priority Review. BridgeBio also issued $933.9 million of 7.00% preferred stock on July 1, 2026, and KKR sold 5,000,000 shares at $78.00 in August 2026.
The bull case: three approval decisions arrive within about six months, and operating losses are nearly gone. The bear case: $550.0 millione of notes come due in March 2027, and the preferred dividend adds $26.3 million of quarterly cost to common holders. With EPS at -$3.78, P/E is not meaningful. The $70.73 close and $13.8 billion market cap reflect October 28, 2026, not today.
What to watch: BBP-418 FDA decision on November 27, 2026; refinancing of the March 2027 notes
03—Filings
Recent SEC Filings
- 8-KBridgeBio Pharma 8-K Report, Financial Results (Oct 29, 2026)BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported third quarter 2026 results on October 29, 2026, with total revenues, net of $353.2 million, compared to $120.7 million in the third quarter of 2025. The increase was driven primarily by U.S. Attruby net product revenue of $253.2 million and a $75.0 million sales milestone from Bayer under the Bayer License Agreement recognized in the quarter. The company reported a loss from operations of $11.6 million and a net loss attributable to common stockholders of $83.0 million, or $0.42 per share, compared to $182.7 million, or $0.95 per share, a year earlier. Cash, cash equivalents and marketable securities were $1.5 billion as of September 30, 2026, up from $587.5 million at December 31, 2025, which the company says will fund its three potential launches and expansion indications. The company highlighted three PDUFA dates within roughly seven months: BBP-418 for LGMD2I/R9 on November 27, 2026, oral infigratinib for achondroplasia on February 4, 2027, and encaleret for ADH1 on May 8, 2027, each with Priority Review. Encaleret also began Phase 3 RECLAIM-HP in chronic hypoparathyroidism, with topline data expected in early 2028. Total operating costs and expenses rose to $364.8 million, driven by higher SG&A spending on commercialization and pre-commercial launch activities, and by higher R&D spending. The company also reported real-world evidence for acoramidis versus tafamidis, including an 18% lower risk of a composite outcome in an Epic COSMOS analysis of 2,684 patients, and new cardiac MRI data from ATTRibute-CM and its extension. Operating expenses and other expense, net of $47.6 million weighed on results, and the filing notes preferred stock dividends and accretion of $26.3 million in the quarter.
- 8-KBridgeBio Pharma 8-K Report, Corporate Update (Oct 13, 2026)BridgeBio Pharma, Inc. (Nasdaq: BBIO) filed this Form 8-K on October 13, 2026, under Item 8.01 (Other Events) to furnish a press release dated October 6, 2026. The press release announces that the FDA accepted for filing the company's New Drug Application (NDA) for oral infigratinib for the treatment of children with achondroplasia, granted Priority Review, and assigned a PDUFA target action date of February 4, 2027. BridgeBio says it is prepared to launch oral infigratinib in the U.S. upon approval. The company cites PROPEL 3, its global Phase 3 pivotal study, which met its primary endpoint of change from baseline in annualized height velocity at Week 52 (mean treatment difference of +2.10 cm/year; p<0.0001) and its key secondary endpoint of change in height Z-score (p<0.0001). The release also reports statistically significant improvements in arm span (z-score +0.37 SD, p<0.0001) and body proportionality (mean difference of -0.05 in ages 3-8, p<0.05, described as a pre-specified exploratory analysis), along with favorable exploratory trends in sleep apnea and otitis media events. The company states that oral infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug. The data were published in The New England Journal of Medicine and presented at the International Congress of Children's Bone Health 2026. The filing also notes that oral infigratinib holds Breakthrough Therapy Designation, Orphan Drug, Fast Track and Rare Pediatric Disease Designations from the FDA, and Orphan Drug Designation from the EMA. BridgeBio intends to submit a Marketing Authorization Application to the European Medicines Agency in the fourth quarter of 2026. The forward-looking statements caution that trial results, regulatory timing, and approval are uncertain.
- 8-KBridgeBio Pharma 8-K Report, Corporate Update (Aug 31, 2026)BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported in an Item 8.01 Other Event filing dated August 31, 2026 that it has entered into a voluntary agreement with the U.S. government to expand access to its medicines and lower costs for American patients. As part of the agreement, BridgeBio will expand state Medicaid access to its currently marketed medicine, Attruby (acoramidis), via the GENEROUS Model. The company states that it does not expect to be subject to future pricing mandates, and that the specific terms of the agreement remain confidential. The company also expects that its pricing commitment for future medicines under the agreement will exclude medicines approved exclusively for orphan indications. The filing states that BridgeBio will continue to offer Attruby via Medicare Part D without any future pricing mandates, and that the agreement has no impact on its ForgingBridges copay assistance program, which can reduce out-of-pocket costs to as little as $0 per month for qualifying patients. The filing's forward-looking statements flag risks, including that the agreement may be implemented or interpreted differently than expected, that additional pricing mandates could be imposed, and that government pricing or reimbursement policies could change. The company's pipeline referenced in the press release includes BBP-418 (PDUFA date with Priority Review: November 27, 2026), encaleret (PDUFA date with Priority Review: May 7, 2027), and infigratinib for achondroplasia, which is under FDA review.
- 8-KBridgeBio Pharma 8-K Report, Material Agreement (Aug 17, 2026)BridgeBio Pharma, Inc. (Nasdaq: BBIO) filed this Form 8-K to disclose a secondary offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company entered into an Underwriting Agreement dated August 13, 2026 with William Blair & Company, L.L.C., Goldman Sachs & Co. LLC and KKR Capital Markets LLC, as representatives of the underwriters, with the shares priced at $78.00 per share. The Company will not receive any proceeds from the sale of the shares, which is expected to complete on August 17, 2026. The offering was made under the Company's effective automatic shelf registration statement on Form S-3ASR (File No. 333-297701), with a prospectus dated July 24, 2026 and a prospectus supplement dated August 13, 2026, filed August 14, 2026. The Company issued a launch press release on August 13, 2026 and a pricing press release on August 14, 2026, which describes the offering as oversubscribed and as diversifying the institutional shareholder base. For investors, the transaction is a secondary sale by an existing holder and does not involve new capital raised by the Company. The filing includes the Underwriting Agreement, a legal opinion from Goodwin Procter LLP, and the related press releases as exhibits.
- 8-KBridgeBio Pharma 8-K Report, Financial Results (Aug 10, 2026)BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported second quarter 2026 results on August 10, 2026, furnished as Exhibit 99.1 to this Form 8-K under Item 2.02. Total revenues, net were $243.7 million for the quarter, comprised of $222.4 million of U.S. Attruby net product revenue, $15.4 million of royalty revenue, and $5.8 million of license and services revenue, compared with $110.6 million in the same period of 2025. Total operating costs and expenses rose to $350.8 million from $244.8 million, and the net loss attributable to common stockholders of BridgeBio was $152.2 million, or $0.78 per share, versus $181.9 million, or $0.95 per share, a year earlier. The company reported $720.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, excluding a $1 billion preferred equity financing led by Sixth Street that closed on July 1, 2026. The company states that all three planned NDAs have now been submitted to the FDA: BBP-418 for LGMD2I/R9 and encaleret for ADH1 were each accepted with Priority Review, with PDUFA target dates of November 27, 2026 and May 8, 2027, respectively, and no advisory committee planned for either. Oral infigratinib for achondroplasia has been submitted, with a U.S. launch expected in mid-2027. Management highlighted new kidney-related post-hoc analyses for Attruby published in Circulation: Heart Failure, along with real-world evidence comparing acoramidis with tafamidis. The company also noted a Commercial Day in New York City on October 8, 2026, and ongoing pipeline expansion efforts including RECLAIM-HP, CALIBRATE-PEDS, and a hypochondroplasia Phase 2 update expected in the second half of 2026.
04—See also
Related Companies
Annual revenue over each company’s last eight fiscal years, each strip on its own scale from zero.